Purpose: We explored the influence of FACBC (fluciclovine) PET/CT on the decision to offer radiotherapy and radiotherapy treatment field recommendations in postprostatectomy patients with recurrent prostate cancer. Patients and Methods: After obtaining institutional review board approval and informed consent, 87 patients with detectable prostate-specific antigen (PSA) levels were recruited into a prospective clinical trial. After an initial provider-determined radiotherapy plan based on conventional imaging, 44 of 87 patients were randomized to additionally undergo fluciclovine PET/ CT. Pre-and post-fluciclovine radiotherapy decisions were compared and changes were noted. Statistical significance of these decision changes was determined. Results: Two of 44 patients in the experimental arm dropped out before fluciclovine scanning. Thirty-four (81.0%) of 42 had positive results on fluciclovine. Overall radiotherapy decision was changed in 17 (40.5%) of 42. Mean PSA, original Gleason score, and prostatectomy-PET interval did not differ significantly between patients with and without radiotherapy decision changes. Two (4.8%) of 42 had the decision for radiotherapy withdrawn due to positive extrapelvic findings. Radiotherapy field decision was changed in 15 (35.7%) of 42. Eleven (73.3%) of 15 had fields changed from prostate bed only to both prostate bed and pelvis, while 4 (26.7%) of 15 had fields changed from both prostate bed and pelvis to prostate bed only. Changes in overall radiotherapy decision and field were statistically significant (P < 0.0001). However, the change in the decision to offer radiotherapy or not was not statistically significant (P = 0.15). Conclusions: Fluciclovine PET/CT significantly changed radiotherapy management decisions in postprostatectomy patients with recurrent prostate cancer. Further work in determining differences in PSA-free survival is ongoing.
A pproximately one fifth of prostate cancer patients have a recurrence within an average of 5 to 6 years after prostatectomy. [1] [2] [3] Salvage radiotherapy, which is often performed for biochemical failure, is fraught with its own challenges, having prostate-specific antigen (PSA) progression-free rates ranging from 18% to 69% within 4 to 7 years of the procedure. 4, 5 Androgen deprivation therapy is another treatment modality in the management of prostate cancer recurrence. 6, 7 Although salvage lymph node dissection is sometimes used, this is not the routine standard of care. [6] [7] [8] The high recurrence rate may be due to the unsatisfactory performance of conventional imaging techniques in disease localization and definition of disease extent, which may account for suboptimal patient selection for salvage radiotherapy. 9, 10 Thus, other imaging techniques, including multiparametric MRI and PET radiotracers, that image molecular pathways and receptors including those of acetate, choline, and prostate-specific membrane antigen (PSMA) among others are being explored to better inform patient management. [11] [12] [13] [14] Anti-1-amino-3-[ 18 F] fluorocyclobutane-1-carboxylic acid (FACBC or fluciclovine) is a fluorinated synthetic amino acid PET radiotracer transported primarily by the amino acid transporters ASCT2 and LAT1, which are overexpressed in prostate cancer. [15] [16] [17] [18] The diagnostic performance of fluciclovine in recurrent prostate cancer has compared favorably to conventional imaging with CT and to radiotracers such as 111 In-capromab pendetide and 11 C-choline. [19] [20] [21] Recent case reports have demonstrated the feasibility of fluciclovine use in planning salvage radiotherapy. 22, 23 Thus we explored this concept more formally via an intention-to-treat clinical trial in which postprostatectomy patients with biochemical failure are randomized to undergo fluciclovine PET/CT after conventional radiotherapy planning. This report is a planned secondary analysis aimed at determining changes in management, specifically the decisions to offer radiotherapy and design of radiotherapy fields after fluciclovine PET compared with the initial decision based solely on conventional imaging.
PATIENTS AND METHODS

Patient Selection
This is a prospective randomized Health Insurance Portability and Accountability Act-compliant clinical trial conducted after institutional review board approval (Clinical Trials.Gov ID: NCT01666808) with arms A and B both consisting of patients with PSA failure after radical prostatectomy for prostate cancer with no evidence of extrapelvic metastasis on bone scan, CT, or MRI. Inclusion criteria included age 18 years or older, Eastern Cooperative Oncology Group performance status of 0 to 2, and postprostatectomy status with detectable PSA levels. Written informed consent was obtained for all patients. Radiotherapy decision for patients in arm A was based on clinical history, pathology findings, PSA trajectory, and conventional imaging only: CT or MRI and bone scan. Patients in arm B (experimental) underwent fluciclovine PET/CT scan after an initial radiotherapy decision based on conventional imaging. Radiotherapy decision in this arm was thereafter modified based on fluciclovine scan results.
Fluciclovine PET/CT Imaging
Fluciclovine was prepared as earlier reported. 21, 24 Patients were scanned on a GE Discovery MV690 PET/CT scanner after at least 4 hours of fasting to normalize amino acid levels. An initial abdominopelvic CT scan was conducted with administration of oral contrast only at 80 to 120 mA and 120 kVp. After this, 8.6 to 10.78 mCi (318.2-398.86 MBq) of fluciclovine was injected intravenously over 2 minutes, with a 3-minute blood pool clearance window; after which, 5 to 15.5 minute and 16 to 27.5 minute images extending from the pelvis to the diaphragm were acquired and data were transferred to a MIMVista workstation (MIM Software; Cleveland, Ohio) for analysis.
Image Analysis
Image interpretation was done independently by 2 boardcertified nuclear medicine physicians. A consensus was reached by both readers on discordant image interpretations. As previously reported, positivity criteria on fluciclovine PET included persistent nonphysiologic moderate (greater than marrow) focal uptake in prostate bed, lymph nodes, or bone. 17 
Decision Criteria
For the purpose of this study, the prostate bed was defined using the Radiation Therapy Oncology Group contouring guidelines. 25 Pre-fluciclovine radiotherapy decision was based on results of conventional imaging using well-recognized clinical criteria 26, 27 and an intention-to-treat form was populated by the treating radiation oncologist.
Post-fluciclovine decision regarding offering radiotherapy and field of radiotherapy was based on imaging findings on fluciclovine PET/CT as follows: (a) patients with no uptake or uptake in the prostate bed only were offered radiotherapy to prostate bed only; (b) patients with uptake in pelvic nodes or pN1 (regional node involvement) were offered standard field radiation to the prostate bed and pelvic nodes; and (c) the decision to give radiotherapy was withdrawn in patients with extrapelvic uptake, and these patients were offered systemic therapy.
Statistical Analysis
Clopper-Pearson (exact) binomial method was used to calculate the statistical significance of the overall decision changes. These include changes in pre-and post-fluciclovine treatment plans regarding (a) the decision to offer radiotherapy or not, (b) the field of radiotherapy (ie, treat prostate bed only or include pelvic nodes), and (c) overall radiotherapy decision that were evaluated. Two-sample t test was used to calculate the statistical significance of differences in PSA levels, Gleason scores, and prostatectomy-fluciclovine interval across both the group that had decision changes and the group that did not. P values less than 0.05 were regarded as statistically significant. Statistical Analysis Software (SAS Version 9.3 SAS Institute Inc, Cary, NC) and Microsoft Excel 2010 were used in data analysis.
RESULTS
Demographics
Eighty-seven patients who met the inclusion criteria were recruited into the study. Forty-four of these were randomized into arm B, but because 2 of these patients did not undergo fluciclovine PET, 42 patients were analyzed in this arm. Full demographic details are provided in Table 1 . All patients had undergone prostatectomy with a mean ± SD (range) of 2.5 ± 2.95 (0-11) years before fluciclovine. The mean PSA ± SD (range) was 2.09 ± 2.96 (0.07-11.15) ng/mL.
Fluciclovine Positivity Rates
On whole-body basis, 34 (81.0%) of 42 patients had positive findings on fluciclovine PET. Detection rates varied with PSA values and improved as PSA level increased (Table 1) . Twelve (35.3%) of 34 were positive in the prostate bed only and 20 (58.8%) of 34 in both bed and pelvis. Despite having no evidence of extrapelvic disease on conventional imaging, 2 (5.9%) of 34 had fluciclovine uptake in extrapelvic regions (Table 1) . Of the 2 who had extrapelvic uptake, one had uptake in the iliac crest and prostate bed, while the other had uptake in retroperitoneal, para-aortic, prevertebral, and pelvic lymph nodes.
Twenty-six of the 42 patients who underwent fluciclovine scans were initially planned for radiotherapy to the prostate bed only (Fig. 1) . Fluciclovine was positive in the prostate only in 9 (34.6%) of 26 and in both the prostate and pelvic regions in 11 (42.3%) of 26. No disease was identified in 6 (23.1%) of 26 of the patients.
Nine (56.25%) of the 16 patients initially planned for radiotherapy to both the prostate bed and pelvis had positive fluciclovine findings in both prostate and pelvis, whereas 3 (18.75%) of 16 had positive findings in only the prostate and 2 (12.5%) of 16 were positive in extrapelvic regions (Fig. 1) . No disease was identified in the remaining 2 (12.5%) of the 16 patients.
Radiotherapy Decision Change
All 42 study participants who underwent fluciclovine PET were initially planned for radiotherapy. As a result of fluciclovine findings, radiotherapy decisions were changed in 17 (40.5%) of 42 patients. There was no significant difference in prognostic factors between patients with and without pre-and post-fluciclovine changes in radiotherapy decisions (Table 2) . Two (4.8%) of 42 patients had radiotherapy decisions withdrawn as fluciclovine found evidence of extrapelvic disease. Figure 2 is an example of fluciclovine uptake in small retroperitoneal nodes in a patient earlier planned for radiotherapy to both prostate bed and lymph nodes but whose treatment was changed to hormonal therapy based on fluciclovine results.
Of the remaining 40 patients who were still to undergo radiotherapy, 15 (37.5%) of 40 had radiotherapy fields changed. Eleven (73.3%) of these 15 had fields increased from the prostate bed only to both the prostate and pelvis, whereas 4 (26.7%) of 15 had fields reduced from both the prostate and pelvis to the prostate bed only. Despite having a negative fluciclovine scan in the prostate bed and pelvis, 1 patient had radiotherapy to both prostate bed and pelvic lymph nodes per accepted clinical criteria as patient had been staged pN1 based on pelvic nodal dissection, which had removed the metastatic node before fluciclovine imaging. Figure 3 shows a positive left internal iliac lymph node seen on fluciclovine in a patient earlier planned for radiotherapy to the prostate bed only. Radiotherapy decision was then modified to include both bed and lymph nodes. Fluciclovine PET/CT also demonstrated bilateral seminal vesicle uptake in a patient earlier planned for radiotherapy to the prostate bed and lymph nodes and is an example of radiotherapy field change to prostate bed only which includes the seminal vesicles (Fig. 4) .
Changes in radiotherapy field and overall radiotherapy decision were both statistically significant (Table 3) . However, change in the decision to offer radiotherapy or not was not statistically significant as only 2 of the patients had a final decision of no radiotherapy.
DISCUSSION
In this study, we set out to determine the role of advanced imaging with fluciclovine in the management of postprostatectomy patients with PSA failure being considered for salvage radiotherapy. Our results show that imaging with fluciclovine significantly altered the radiotherapy treatment decision in these patients. Seventeen (40.5%) of our 42 patients had a change in radiotherapy decision after fluciclovine PET/CT. Fifteen (35.7%) of 42 had their radiotherapy fields changed after fluciclovine PET/CT. Two (4.8%) of 42 were instead offered hormonal therapy due to systemic disease. Data from previous studies have shown that fluciclovine PET/CT is useful in the restaging of prostate cancer patients. 28 However, this study shows the findings on fluciclovine PET could potentially be useful for salvage therapy planning as well, though this would need to be validated by improvement in PSA-free survival, which is an ultimate end point of the trial.
Our findings are important since a wide range of factors including imaging results, PSA, PSA doubling time, and Gleason score are considered before the decision to offer and design salvage radiotherapy is made. [29] [30] [31] With poor patient selection being a possible contributor to the high biochemical failure rates after salvage radiotherapy, [32] [33] [34] accurate imaging to improve patient selection is critical. Although radioimmunoscintigraphy against PSMA has been studied, [35] [36] [37] current treatment planning mostly relies on conventional imaging, which may be unrevealing in the initial stages of prostate cancer recurrence. 10, 11, 21, 38, 39 Therefore, molecular imaging techniques such as fluciclovine that have shown promise in more accurately restaging prostate cancer patients may potentially prove useful in salvage radiotherapy selection and planning by reducing overtreatment or undertreatment of these patients.
Our findings are comparable to other studies using PET techniques in assessing the influence of molecular imaging in treatment decisions regarding recurrent prostate cancer management. In a study on the use of 11 C-choline PET/CT in treatment planning in recurrent prostate cancer, 13% of the 37 patients in the study had modifications to the earlier planned radiotherapy field compared with 35.7% in our own study. 40 In another study involving 150 patients, 95 of who were planned for salvage radiotherapy, 11 C-choline PET/CT resulted in therapy adjustment in 33.7% of patients earlier planned for salvage radiotherapy and change to another form of therapy in 13.7%. 41 18 F-fluorocholine PET/CT also influenced treatment decisions in patients with recurrent prostate cancer and resulted in a change in earlier planned therapy in 48% of the 156 patients in the study. 42 Radiotherapy decision management after PSMA PET/CT imaging in prostate cancer patients has also been studied with a reported radiotherapy change in 46.3% to 54.8% of patients after PSMA PET/CT. 43, 44 Sterzing et al 45 also found a similar (50.8%) change in radiotherapy approach in 29 of 57 patients in their study, 25 of whom were postprostatectomy.
Overall in our study, fluciclovine demonstrated areas of positivity in 34 (81.0%) of 42 patients. Detection rates varied with PSA values and generally improved as PSA level increased with values of 72.0%, 83.3%, and 100% at PSA levels <1, 1 to <2, and ≥2 ng/mL, respectively. The trend of improved detection rates with increasing PSA is similar to that seen with other radiotracers. 46, 47 Yet further study is required because, in a study from the Bologna group with a similar population of postprostatectomy patients, FIGURE 2. Extrapelvic uptake on fluciclovine scan. Retroperitoneal lymph node −0.5 to 1 cm (arrows) uptake on CT (A), PET/CT (B), and PET/CT coronal plane (C) in a 72-year-old patient earlier planned for radiotherapy to prostate bed and pelvis. Radiotherapy decision was withdrawn after FACBC and hormonal therapy offered (PSA level, 3.46 ng/mL). the reported detection rate for fluciclovine was 21% with PSA level <1 ng/mL. 19 We have also described a detection rate of 39.0% at PSA values <1 ng/mL in an earlier study on a mixed posttherapy population 48 and have more recently reported that detection rate increases with shorter doubling times. 20 Interestingly, post hoc analysis of the PSA level <1 ng/mL cohort in each of these studies demonstrates a shorter doubling time mean ± SD (4.4 ± 13.0 months) in this study corresponding to the higher detection rate versus a longer doubling time (13.9 ± 19.9 months) in the earlier report corresponding to a lower detection rate.
Studies assessing the detection rate of 11 C-choline PET/CT in patients with recurrent prostate cancer have yielded varying range of values with rates of 36%, 43%, 62%, and 73% at PSA <1, 1 to <2, 2 to <3, and ≥3 ng/mL, respectively, reported in one study. 49 In another study, rates of 19%, 25%, 41%, and 67% at PSA levels of ≤1, >1 to ≤2, >2 to ≤5, and >5 ng/mL, respectively, were reported with the same radiotracer. 50 68 Ga-PSMA PET/CT is in an earlier stage of development but has reported high sensitivity with detection rates of 57.9%, 72.7%, 93.0%, and 96.8% at PSA levels of 0.2 to <0.5, 0.5 to <1, 1 to <2, and ≥2 ng/mL, respectively. 51 The current study has certain limitations: First, the results are those of a planned analysis of a secondary end point of the study. As such, the trial has not reached its final accrual goal (which would involve 81 patients each on the control and fluciclovine arms). However, the strong statistical significance of the decision changes on the current/interim sample is encouraging. Second, although preand post-fluciclovine decisions were captured, the pre-fluciclovine radiotherapy decisions were based on a constellation of items including patient history, prostatectomy pathology findings, and PSA trajectory. However, the study does span several radiotherapy providers so the pre-fluciclovine decisions are likely to be a representative cross section of those made in the prostate radiotherapy community.
In conclusion, the decision to offer radiotherapy in recurrent prostate cancer can be challenging. Careful consideration and proper patient selection is essential to ensure favorable outcomes. 5, 32, 34, 52 Use of fluciclovine PET/CT in patients being considered for salvage radiotherapy has demonstrated in this interim analysis a 40.5% overall change in therapy decision, with 4.8% having radiotherapy withdrawn and 35.7% having a change in radiotherapy fields. Further in a 60-year-old patient earlier planned for radiotherapy to prostate bed and pelvis only. Radiotherapy decision was thereafter changed to radiotherapy to prostate bed only (PSA, 1.1 ng/mL). 
